Showing 1,121 - 1,140 results of 10,117 for search 'significantly ((((((we decrease) OR (linear decrease))) OR (mean decrease))) OR (greater decrease))', query time: 0.38s Refine Results
  1. 1121

    Top-level overview for ADHD classification study. by Ahmed Akib Jawad Karim (20427740)

    Published 2025
    “…Referring to LastBERT, a customized student BERT model, we significantly lowered model parameters from 110 million BERT base to 29 million-resulting in a model approximately 73.64% smaller. …”
  2. 1122

    NIE ELISA results. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”
  3. 1123

    Kato Katz and PCR database 12 months collection. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”
  4. 1124

    Master database baseline, 4 weeks and 1 year. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively (<i>p</i><0.001, both comparisons). …”
  5. 1125
  6. 1126
  7. 1127
  8. 1128
  9. 1129
  10. 1130
  11. 1131

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  12. 1132
  13. 1133
  14. 1134

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  15. 1135

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  16. 1136

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  17. 1137
  18. 1138

    Questionnaire description. by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    “…<div><p>Background</p><p>During the last decades, intensive care unit (ICU) mortality rates have significantly decreased but this progress has come with unintended consequences for patients and their caregivers. …”
  19. 1139
  20. 1140